Randomized Trialvery high evidence
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.
Nature medicine·July 1, 2024·PMID 38740993
Why it mattersThis analysis provides the longest-term evidence to date on semaglutide's weight loss durability and safety in a high-cardiovascular-risk population without diabetes, supporting its role in chronic weight management and potentially informing cardiovascular risk reduction strategies.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled